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ABSTRACT
Aging and cancer are two interrelated processes, with aging being a major risk factor for the development of cancer. 
Parallel epigenetic alterations have been described for both, although differences, especially within the DNA 
hypomethylation scenario, have also been recently reported. While many of these observations arise from the use of 
mouse models, there is a lack of systematic comparisons of human and mouse epigenetic patterns in the context of 
disease. However, such comparisons are significant as they allow to establish the extent to which some of the observed 
similarities or differences arise from pre-existing species-specific epigenetic traits. Here, we have used reduced 
representation bisulfite sequencing to profile the brain methylomes of young and old, tumoral and non-tumoral brain 
samples from human and mouse. We first characterized the baseline epigenomic patterns of the species and subsequently 
focused on the DNA methylation alterations associated with cancer and aging. Next, we described the functional genomic 
and epigenomic context associated with the alterations, and finally we integrated our data to study interspecies DNA 
methylation levels at orthologous CpG sites. Globally, we found considerable differences between the characteristics of 
DNA methylation alterations in cancer and aging in both species. Moreover, we describe robust evidence for the 
conservation of the specific cancer and aging epigenomic signatures in human and mouse. Our observations point towards 
the preservation of the functional consequences of these alterations at multiple levels of genomic regulation. Finally, our 
analyses reveal a role for the genomic context in explaining disease- and species-specific epigenetic traits.
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INTRODUCTION
Aging is one of the main risk factors associated with the development of cancer. These two processes have been 
extensively investigated from the epigenetic perspective and consequently analogous epigenetic alterations have been 
identified for both, providing explanations for the possible molecular links between them (Aunan et al. 2017; Yu et al. 2020). 
These alterations mainly relate to local gains in DNA methylation at CpG-dense regions and global losses at the genomic 
scale involving repetitive DNA (Baylin and Jones 2016; Sen et al. 2016). Nonetheless, the extent of these parallelisms has 
not as yet been clearly outlined, particularly within the hypomethylation scenario (Dmitrijeva et al. 2018; Pérez et al. 2018). 
Moreover, recent whole-genome studies in mouse have also failed to confirm hallmarks such as global hypomethylation 
with aging in tissues including liver, hippocampus and stem cells (Sun et al. 2014; Cole et al. 2017; Cole et al. 2017; Hahn 
et al. 2017; Masser et al. 2017; Hadad et al. 2019; Hernando-Herraez et al. 2019). These observations underscore two 
different, but equally important, issues: first, there is a need to study aging- and cancer-associated epigenetic patterns in 
a systematic manner to facilitate an integrated comparison between the two processes; second, it is essential to also 
confirm whether aging- and cancer-associated epigenetic alterations are equivalent in human and mouse models, as the 
latter are very important experimental proxies of human biology.
Mouse models have been widely used in the characterization of landmark epigenetic mechanisms such as 
transgenerational inheritance and genomic imprinting (Blewitt and Whitelaw 2013) as well as developmental epigenomic 
reprogramming (Hanna et al. 2018), and they are often used to characterize alterations in specific disease-associated 
pathways which sometimes have a translational correspondence in human (Espada and Esteller 2013). To date, reports 
suggest that DNA methylation patterns preserve global features such as the presence of non-methylated islands and gene 
body methylation across mammalian species in general (Long et al. 2013; Schroeder et al. 2015), with other parallelisms 
extending across more distant vertebrate taxa (Elango and Yi 2008). More directed comparisons involving mouse and 
human have described a general conservation of their genome-wide epigenetic patterns (Edwards et al. 2010) and have 
particularly focused on the interspecies conservation of tissue-specific methylation patterns (Kessler et al. 2016; Zhou et 
al. 2017; Chen et al. 2018) and developmental processes (Lister et al. 2013). Nonetheless, considerable epigenetic 
differences in proximal species such as primates have been reported (Hernando-Herraez, Heyn, et al. 2015; Mendizabal 
et al. 2016). So far there have been only limited high-resolution studies that focus on directly assessing specific epigenetic 
similarities between human and mouse in either aging (Maegawa et al. 2017; Wang et al. 2017) or cancer (Maegawa et 
al. 2014), and those that exist are often limited by their compilation of data from different studies or the use of different 
profiling technologies for each species. Some of these issues have arisen from the lack of a large-scale DNA methylation 
array technology for mouse. Overall, then, there is a lack of back-to-back human-mouse comparisons of DNA methylation 
at single-base resolution in the context of disease. Even so, this issue is particularly relevant in the study of DNA 
methylation alterations found independently in both species in order to reliably ascertain the extent to which some of the 
observed similarities or differences arise from pre-existing species-specific epigenetic traits.
In this study we sought to perform a systematic, integrated and intercomparable analysis of the DNA methylation dynamics 
associated with cancer and aging in both human and mouse. To this end, we profiled the brain methylomes of young and 
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old, tumoral and non-tumoral brain samples from human and mouse by reduced representation bisulfite sequencing 
(RRBS), which provided a robust and interspecies-comparable platform for the analysis at hand (Bock et al. 2010). We 
first characterized the baseline epigenomic patterns of both species and subsequently focused on the DNA methylation 
alterations associated with cancer and aging. Next, we described the functional genomic and epigenomic context 
associated with the alterations, and finally we integrated our data to study interspecies DNA methylation levels at 
orthologous CpG sites. Globally, we found considerable differences between the genomic and epigenomic characteristics 
of DNA methylation alterations in cancer and aging in human and mouse. Furthermore, we describe robust evidence for 
the conservation of the specific cancer- and aging-associated epigenomic patterns in both species. Our observations point 
towards the preservation of the functional consequences of these alterations at multiple levels of genomic regulation, 
including the locations and chromatin context of the alterations, the genetic pathways and transcription factors involved. 
Additionally, the analysis of orthologous CpG loci allowed us to describe species-common locations of DNA methylation 
variability and species-common cancer- and aging DNA methylation alterations. Finally, our analyses suggest that the 
genomic context associated with many CpG sites may help explain the observation of species-discordant DNA methylation 
as well as cancer and aging-specific DNA methylation alterations. 
RESULTS AND DISCUSSION
Baseline epigenomic patterns are conserved between human and mouse
To characterize the intricate, conserved epigenetic signatures that may exist in aging and cancer, we studied the genome-
wide DNA methylation patterns of young, old, tumoral and non-tumoral brain samples from human and mouse (n = 24, 3 
per group, Fig. 1A). We produced methylation values for an average of 3.94 million and 1.62 million unique CpG sites per 
sample for human and mouse, respectively, and retained a final total of 1,171,918 and 585,234 CpG sites common to all 
samples after filtering for coverage (see Methods and supplementary table 1 for sample and alignment information). We 
first sought to characterize the global aspects of DNA methylation and its relationship with genomic function in the two 
species in order to determine the baseline similarities and differences in DNA methylation patterns in our study system. 
For this initial analysis we focused on the non-tumoral samples because the tumors showed extensive deviation from the 
rest of the samples using pairwise Pearson correlations (Fig. 1B), and our goal was to profile the general species-wise 
features of DNA methylation in our samples.
While significant, we did not observe noticeable differences between the species in the distribution of the overall 
methylation values, with an average methylation of 0.266 for human and 0.272 for mouse (Fig. 1C, Wilcoxon rank-sum p-
val = 0.02). The low levels of methylation observed are to be expected since the RRBS technology targets CpG-dense 
regions, such as CpG islands, which tend to be unmethylated. On a genome-wide scale, however, most CpG sites are 
methylated in mammals (Greenberg and Bourc’his 2019), and technologies such as whole genome bisulfite sequencing 
(WGBS), which also targets intergenic regions, would detect higher levels of DNA methylation.
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In order to ascertain that the RRBS was evaluating a comparable population of CpGs for each species, we annotated the 
sites to functional genomic locations in terms of their CpG island membership status and genetic elements. For both 
species, the technology interrogated a majority of CpG sites located at CpG islands (Fig. 1D), with a slight increase in 
open sea CpGs for mouse (Fisher’s p-val < 0.001, OR = 1.89). Regarding genetic elements, the distribution of the 
quantified CpGs was also very similar for both species (Fig. 1E), with the largest proportion of sites being located at 
promoters and gene bodies. These observations suggest that, for human and mouse, the RRBS technology targets 
populations of CpG sites which have analogous genomic contexts.
Next, we proceeded to characterize the relationship between DNA methylation and CpG context in both human and mouse. 
With respect to CpG islands, DNA methylation was highest at open sea locations and lowest at islands for both species, 
with a transition in methylation across shelves and shores (Fig. 1F). For gene elements, the relationship with DNA 
methylation was also parallel between human and mouse, with promoters and 5’UTR regions showing the lowest values, 
followed by gene body exons and introns, while intergenic regions were those with the highest DNA methylation (Fig. 1G). 
The presence of DNA methylation is inversely correlated to the density in surrounding CpG sites (Chen et al. 2018), and 
this may help explain some of the patterns found at genomic locations, especially concerning CpG islands and open sea. 
We therefore characterized the density in the CpG sites associated with each locus by counting the number of neighboring 
CpG sites in surrounding 2 kb windows. As expected, in general, low methylation values were found associated with 
locations with higher density in CpG sites, while higher methylation values were found at low density locations, for both 
species (Fig. 1H). Indeed, the different genomic locations (islands and gene regions) displayed different distributions of 
density in CpG sites (Fig. S1A) and, moreover, the mean methylation value of each element correlated almost perfectly 
with its average density in CpG sites (Fig. S1B). Collectively, these results confirm that the relationship between DNA 
methylation and functional genomic elements such as CpG islands and gene regions is conserved between human and 
mouse and is mostly explained by the density of CpG sites associated with each element (Edwards et al. 2010).
In the regulation of gene expression, epigenetic marks such as DNA methylation are not independent, rather, they act in 
combination with interrelated marks such as histone modifications to define functional states (Du et al. 2015). Thus, to 
better study the relationship of DNA methylation concerning its genomic function in mouse and human, we integrated our 
data with ENCODE and NIH Roadmap Epigenomics ChIP-seq data profiling the histone modifications H3K4me1, 
H3K4me3, H3K27ac, H3K36me3, H3K27me3 and H3K9me3. We focused on a panel of tissues which were available for 
the two species, and contained several brain tissue tracks, analysing a combined total of 144 datasets. We classified CpG 
sites as high-, medium- or low-methylation loci (> 0.8, [0.2,0.8] and < 0.2 average methylation values, respectively) and 
investigated the co-localization of these sites with the histone marks by over-enrichment analyses at FDR < 0.05 (see 
Methods). With this procedure we observed practically identical chromatin signatures of methylation status in human and 
mouse (Fig. 1I and supplementary table 2): high methylation sites were associated with active gene-body H3K36me3 
and repressive H3K9me3 marks, intermediate methylation also appeared to be related to enhancer/promoter-associated 
H3Kme1 and low methylation sites were strongly associated with the active promoter and enhancer H3K4me3 and 
H3K27ac marks. These observations confirm that the relationship between DNA methylation and genomic function is 
conserved in both species (Roadmap Epigenomics Consortium et al. 2015; Gorkin et al. 2020).
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One of the genomic elements to which DNA methylation has been most functionally linked is repetitive DNA (Beisel and 
Paro 2011). Hence, we mapped the classified CpG sites to RepeatMasker repetitive elements and looked for over-
enrichment in specific repeat classes. Looking at the most common repeats, we observed, for both human and mouse, 
that high-methylation loci were associated with SINE, LINE, LTR and DNA repeats, while low-methylation was linked to 
simple and low-complexity repeats (Fig. 1J and supplementary table 3). Expanding the analyses to repetitive element 
families also revealed parallel patterns in the two species (Fig. S2). These results are also in consonance with existing 
literature both for mouse and human (Edwards et al. 2010).
Dynamics of DNA methylation alterations in human aging and cancer
Once we had confirmed the analogous human and mouse baseline epigenomic patterns in our study system, we 
proceeded to determine the DNA methylation alterations associated with aging and with cancer for each species 
independently. Starting with human, we found no general DNA methylation differences associated with cancer or aging by 
looking at all the sites analysed by the RRBS, although tumor samples tended to have higher methylation values (Fig. 
2A). Moreover, PCA clustering suggested differences between the experimental groups as they segregated across the 
most meaningful dimensions (Fig. 2B). We performed a differential methylation analysis with a stringent threshold (FDR 
< 0.05, average change in methylation > 0.2) to define differentially methylated CpGs (dmCpGs) in aging and cancer. We 
identified widespread alterations in both processes, counting 154,770 dmCpGs associated with cancer and 66,838 with 
aging (lists of dmCpGs are available as extended datasets), with hypermethylation dominating the cancer scenario 
particularly (accounting for 72% of changes, Fig. 2C-D). Furthermore, performing the cancer differential methylation 
comparison using all 9 non-tumoral samples (non-tumor, young and old groups) as the control group yielded comparable 
results and numbers of dmCpGs (Fig. S3A), indicating that the cancer-associated alterations observed are robust and are 
independent of the samples used. When mapping the dmCpGs to CpG island locations (Fig. 2E), we observed that 
hypermethylation occurred for cancer preferentially at CpG islands, with a distribution akin to that of the RRBS background 
of analysed sites, while hypomethylation and aging-associated changes were, in general, enriched at open sea locations 
(Fisher’s p-vals < 0.001, ORs = 8.9, 3.3 and 4.0, respectively). Regarding gene locations, cancer hypomethylation and 
aging hyper- and hypomethylation were particularly increased at intergenic- and intronic sequences (Fisher’s p-vals < 
0.001, intergenic ORs = 4.5, 2.0 and 2.0, intronic ORs = 1.8, 1.7 and 2.0). In line with this observation, cancer 
hypermethylation occurred more frequently at CpG-denser regions than the rest of the changes (Fig. S3B) and, additionally, 
it consisted of the strongest changes (Fig. S3C). These results suggest that there are important differences in the breadth 
and distribution of hyper- and hypomethylation alterations in cancer, while aging-associated alterations appear to be 
located at similar genomic locations regardless of the direction of change, these locations being comparable to those 
targeted by cancer-associated hypomethylation.
To expand on the possible functional consequences of the DNA methylation alterations observed, we mapped the dmCpGs 
to genes and performed pathway enrichment analyses. First, as shown in Fig. 2F, the largest proportion of dmCpGs 
mapping to genes was found for cancer hypermethylation. However, of the CpGs that mapped to genes, cancer hypo-
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dmCpGs and aging dmCpGs, although less numerous, were distributed across similar numbers of genes as cancer hyper-
dmCpGs (Fig. 2G, Chi-squared p-val < 0.001), indicating that the former were more spread-out across different genes. 
We performed pathway enrichment analyses against several databases which included Gene Ontology, KEGG and 
Reactome pathways, and the CGP database from MSigDB, which describes empirical pathways mined from biomedical 
literature. Only cancer hyper-dmCpGs revealed significant enrichment in biological functions, and these were related to 
Polycomb-target genes, G-protein coupled receptor (GPCR) pathways—with neuropeptide receptors in particular—and 
cellular development pathways, especially neuronal (Fig. S4, full results are available as extended datasets). Thus, 
cancer-associated DNA methylation deregulation, particularly hypermethylation, appears to have a more coherent 
functional impact than aging-associated changes.
In order to investigate common axes of DNA methylation deregulation in both cancer and aging, we intersected the 
dmCpGs found, observing common CpG sets across all processes (Fig. 2H and supplementary table 4). These 
intersections were all significantly over-enriched (SuperExactTest all p-val < 0.001), with common cancer- and aging hypo-
dmCpGs displaying the highest fold enrichment, while common cancer hyper- and aging hypo-dmCpGs showed the lowest. 
These findings indicate that, regardless of their direction of change, DNA methylation alterations are readily found at 
disease-common loci. We performed pathway enrichments on these intersections and only observed enrichments in 
common CpGs between cancer hypermethylation and aging hyper- and hypomethylation (full results are available as 
extended datasets). These results suggest that the functional commonalities between DNA methylation deregulation in 
human cancer and aging mainly pertain to Polycomb-target gene hypermethylation in cancer, whereas these pathways 
manifest both hyper- and hypomethylation in aging. 
Dynamics of DNA methylation alterations in mouse aging and cancer
Next, we profiled the DNA methylation alterations associated with aging and cancer in mouse. First, regarding the general 
levels of DNA methylation, we found, in line with the previous observations in human, an even clearer trend of increased 
DNA methylation in cancer (Fig. 3A). The PCA hinted at some differences between the phenotypes in that a slight 
separation was observed between the groups when looking at the top 2 dimensions (Fig. 3B). The differential methylation 
analysis (FDR < 0.05, average change in methylation > 0.2) uncovered extensive alterations, with 181,027 dmCpGs 
detected in cancer and 22,564 in aging (lists of dmCpGs are available as extended datasets). When all of the 9 non-
tumoral samples (non-tumor, young and old groups) were used as the control group in the cancer differential methylation 
comparison, results and numbers of dmCpGs were similar (Fig. S5A), suggesting that the cancer-associated alterations 
observed are readily detected irrespective of the samples used. Regarding the direction of the alterations, 
hypermethylation was the predominant phenomenon in both processes (accounting for 68% and 62% of changes, 
respectively, Fig. 3C-D). The genomic-location distributions of the dmCpGs were analogous to those observed in the 
human system (Fig. 3E): cancer hypermethylation occurred at CpG island-associated sites while cancer hypomethylation 
and aging hyper- and hypomethylation changes were much more enriched at open sea locations (Fisher’s p-vals < 0.001, 
ORs = 24.7, 6.7 and 10.3). Similarly, with respect to gene locations, these latter alterations were once more enriched at 
intergenic and intronic sequences (Fig. 3F, Fisher’s p-vals < 0.001, intergenic ORs = 7.5, 2.4 and 3.0, intronic ORs = 1.6, 
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2.3 and 2.1, respectively). Again, cancer hypermethylation was directly associated with higher CpG-density (Fig. S5B) 
and accounted for the largest alterations (Fig. S5C). In general, the patterns of disease-associated DNA methylation 
changes, and especially the contrast between cancer and aging alterations, followed the same trends as those seen for 
human tissue.
To examine if the parallelisms observed extended to the functional pathways involved, we mapped the dmCpGs to genes 
and carried out pathway enrichment analyses. Once more, within the dmCpGs mapping to genes, despite cancer hyper-
dmCpGs being by far the most numerous, they were concentrated across fewer genes than expected when compared to 
hypo-dmCpGs and aging changes (Fig. 3G, Chi-squared p-val < 0.001). In this case, the pathway enrichment analyses 
revealed significant results for all sets of dmCpGs (Fig. S6, full results are available as extended datasets). Cancer hyper-
dmCpGs, as with human, were enriched in Polycomb-target genes, GPCRs (Wnt-activated in particular) and cellular 
development pathways, including neuronal ones. On the other hand, hypo-dmCpGs were enriched in generic cancer 
pathways, cell-signalling pathways (including GPCRs) and inflammation terms. Aging hypermethylation was enriched in 
cell-interaction terms, and hypomethylation in cell-signalling pathways. These results indicate that, in contrast to human 
processes, aging-associated DNA methylation alterations in mouse may have more directed functional consequences at 
the gene level.
We integrated the cancer- and aging-associated dmCpGs and found significant over-enrichment for all the common sets 
(Fig 3H and supplementary table 4, SuperExactTest all p-val < 0.001). As occurred with human tissue, while all the 
intersections displayed over-enrichment, common cancer- and aging hypo-dmCpGs displayed the highest fold enrichment 
and cancer hyper- along with aging hypo-dmCpGs the lowest. Next, we performed pathway enrichment analyses of the 
intersections. This time, we observed no significant enrichments for those containing cancer hyper-dmCpGs, but modest 
enrichments for inflammation terms did appear, especially for cancer hypo- and aging hyper-dmCpGs (full results are 
available as extended datasets). Taken together, these results suggest that, in the case of mouse and, in contrast to the 
human results, the Polycomb-target, developmental gene hypermethylation observed in cancer is not as evident in aging.
The interspecies genomic context of cancer and aging DNA methylation alterations
In light of the parallelisms observed, we sought to extend the analyses to additional levels of epigenomic regulation by 
integrating the methylomic data with the previously mentioned histone modification data—involving the histone 
modifications H3K4me1, H3K4me3, H3K27ac, H3K36me3, H3K27me3 and H3K9me3—across a panel of common healthy 
tissues in human and mouse (see Methods). We performed over-enrichment analyses (FDR < 0.05) to test the association 
of the cancer- and aging-related dmCpGs discovered in the two species with the different histone modifications, in order 
to define chromatin signatures linked to the DNA methylation changes. Using this procedure, we were able to find robust 
and well-defined similarities between the two species (Fig. 4A and supplementary table 5). As regards cancer-associated 
changes, we observed an association of DNA hypermethylation with the repressive H3K27me3 modification and the more 
active enhancer/promoter-associated H3K4me1. In the case of human, cancer hypermethylation was also strongly 
enriched at H3K9me3 locations, which are linked to heterochromatic and repressive states. On the other hand, cancer 









sab112/6237917 by guest on 20 April 2021
9
hypomethylated dmCpGs were mainly enriched in the H3K9me3 mark for both species. These cancer-associated 
signatures have been described across multiple tissues for human (Pérez et al. 2018) while the literature for mouse is 
scant.
When looking at aging-related signatures, we again found comparable patterns between human and mouse. Moreover, 
for both species, these patterns were markedly different to those found for cancer. We observed enrichments at locations 
marked with gene-body H3K36me3, heterochromatin H3K9me3 and enhancer/promoter H3K4me1. In this case, even 
though we observed an increase in H3K4m1 association at aging hypomethylated loci when compared to aging 
hypermethylation—a finding reported for human in several tissues (Fernández et al. 2015; Pérez et al. 2018)—the global 
patterns of enrichment found for aging dmCpGs differed moderately from those described in the literature, a result which 
could have been influenced by the fact that the “classical” chromatin signatures have been mostly derived by using array 
technology, which targets similar but not identical genomic contexts (Fig. S7). In further support of this idea, a recent study 
comparing aging-associated DNA methylation changes in liver between human and mouse—using array and RRBS data 
for each species respectively—reported a high enrichment in H3K36me3-associated loci specifically for mouse aging 
changes as compared to human (Wang et al. 2017).
Because the histone modification results exposed epigenomic similarities between human and mouse for the methylation 
changes associated with cancer and aging, we extended our analyses to discover and study chromatin states, which are 
defined by spatial combinations of the histone marks and reflect functional genomic states (Ernst and Kellis 2010). We 
trained 18-state models using the 6 core histone modifications for our selected panel of datasets by using multivariate 
Hidden Markov Models (see Methods). The nature of the human states defined was similar to that previously described 
(Roadmap Epigenomics Consortium et al. 2015) in terms of their histone mark composition and co-occurrence with other 
genomic elements (Fig. S8A). The states found for mouse were, in turn, notably similar to human (Fig. S8B), with the 
exception of some specific ones, such as the one assigned as “EnhG2” (genic enhancer 2). These observations suggest 
that multi-level epigenomic regulation is functionally parallel between the two species.
We evaluated the over-enrichment of the dmCpGs in the different chromatin states (Fig. 4B and supplementary table 6). 
Cancer hypermethylation was strongly enriched in bivalent transcription start sites and Polycomb-repressed sites (states 
14, 16), and somewhat enriched in transcription start sites and enhancer sites in general (states 2-4, 7-11) for both species. 
Additionally, and as suggested by the stronger enrichment in H3K9me3 for human as compared to mouse (Fig. 4A), the 
chromatin-state analysis revealed that cancer hypermethylation also occurred, specifically for human, both at 
heterochromatic regions and at zinc-finger (ZNF) genes/repeats (states 12, 13). Indeed, ZNF genes, which are 
characterized by the high presence of H3K9me3 (Blahnik et al. 2011), displayed the highest over-enrichment of all the 
chromatin states in human cancer hypermethylation. Interestingly, this family shows a great evolutionary expansion in 
human as compared to other species, including mouse, and its members are posited to play roles in novel transcriptional 
repression activity (Emerson and Thomas 2009). Thus, the DNA methylation deregulation observed in human cancer could 
be related to the targeting of human-specific pathways. Regarding cancer hypomethylation, for both species most of the 
affected chromatin states (13, 15, 17, 18) involved repressive functions, such as heterochromatin or Polycomb-associated 









sab112/6237917 by guest on 20 April 2021
10
sites, with some enrichment also being observed in various enhancer associated states. In the case of aging-associated 
dmCpGs, and much like with the histone signatures, the enrichments were spread out across similar states for hyper- and 
hypomethylation, and involved gene-body transcription states (5, 6), enhancer states (7-11) and repressive states (15-18). 
Especially in the case of human, a particular increase in enrichment in enhancer states was observed for aging 
hypomethylation. The human and mouse profiles were globally similar, with some differences, such as in EnhG2 (state 8) 
probably being explained by the pre-existing differences in the chromatin models built (Fig. S8). Collectively, our results 
show that the chromatin context of DNA methylation changes in cancer and aging is considerably different, and that the 
specific features of each process are robustly recapitulated in human and mouse.
We also looked at the association between DNA methylation alterations and repetitive DNA elements (Fig. 4C and 
supplementary table 7; see Fig. S9 for the analysis expanded to repetitive DNA classes). First, regarding cancer, 
repetitive loci were mainly associated with hypomethylation across the same large classes of repeats (SINE, LINE, LTR, 
DNA), as has been well-described previously (Ross et al. 2010), with the main species difference being that satellite 
repeats showed no changes in DNA methylation for mouse (Fig. 4C). In the case of SINE repeats, both the primate-
specific Alu family in human and the related B elements (B1, B2, B4) in mouse were targeted by DNA hypomethylation 
(Fig. S9). Interestingly, we also observed in human the hypermethylation of ribosome-associated elements (rRNA, 
srpRNA), a finding which has been reported for some types of cancers (Srivastava et al. 2016), although literature on the 
subject is scarce. Secondly, in the case of aging, both hyper- and hypomethylation were associated with repetitive DNA, 
with the patterns observed being similar to those of cancer hypomethylation. Although RRBS is mostly limited to examining 
single-copy sequences, the bi-directionality of the changes found here for aging may help explain observations in the 
literature that fail to describe any noticeable trend of loss of methylation during aging in the genome-wide levels of brain 
methylation both in mouse (Hadad et al. 2019) and human (Lister et al. 2013; McKinney et al. 2019). No associations 
whatsoever were found with simple or low-complexity repeats, which were the main classes which we had previously 
linked to low levels of basal methylation in non-tumoral tissue (Fig. 1J). Taken together, these observations suggest that 
repetitive DNA elements are subject to similar DNA methylation alterations in cancer and aging for both species, with the 
exception of satellite repeats, which appear to be more affected by these processes in human as compared to mouse.
We next sought to study the possible effects of the DNA methylation changes found at transcription factor (TF) binding 
sites, because TFs are downstream genomic regulators directly in contact with the genomic structure. To this end, we 
performed a HOMER analysis to find enrichment in TF motifs associated with dmCpG sites, selecting the top 50 significant 
(FDR < 0.05) motifs with the highest enrichments found for each comparison (see supplementary table 8 for extended 
results). First, to obtain a general overview of the types of TFs affected by the DNA methylation changes, we classified 
our results into TF domain-families (Fig. 4D). With this approach, we found both similarities and differences between the 
processes as well as between species. Cancer hypermethylation dmCpGs were associated with Homeobox TFs for both 
species (Fisher’s p-vals < 0.01, ORs = 2.7 and 2.7 for human and mouse, respectively), but also associated with NRs in 
human (Fisher’s p-val < 0.05, OR = 2.8) and bHLH-domain TFs (Fisher’s p-val < 0.001, OR = 7.8) in mouse. Regarding 
cancer hypomethylation, it was particularly enriched at bHLH- and HMG-domain TF motifs in human (Fisher’s p-vals < 
0.001, ORs = 11.4 and 8.8, respectively). On the other hand, the patterns of TF sites targeted by aging hyper- and 
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hypomethylation were similar in both species. Aging hypermethylation particularly affected ETS-domain TF motifs (Fisher’s 
p-vals < 0.001, ORs = 48.5 and 26.9 for human and mouse, respectively) while hypomethylation involved bHLH- and HMG-
domain TF sites (Fisher’s p-vals < 0.001, ORs = 6.9, 12.0, 7.8 and 16.6 for human bHLH, HMG and mouse bHLH, HMG, 
respectively).
Subsequently, we focused on the specific TFs involved in the previous observations, by looking at the main sets of shared 
or unique TFs affected in each comparison (Fig. S10). As suggested by the previous results, the patterns of species-
common alterations at TF motifs were especially noticeable for aging-related changes. Aging-associated hypermethylation 
of ETS-domain TFs, a family strongly linked to oncogenic processes (Sizemore et al. 2017), was the main common 
epigenetic phenomenon between mouse and human. Several Sox TFs (HMG domains) were commonly targeted by aging 
hypomethylation in both species, such as Sox2, whose expression has been shown to be deregulated with aging in both 
human and mouse brain (Carrasco-Garcia 2018). Interestingly, Sox TFs also appeared affected by cancer 
hypomethylation in human, suggesting possible links between the regulation of aging and of cancer, as has been shown 
for Sox4 in other tumors (Foronda et al. 2014). In addition, the deregulation of methylation patterns at bHLH-domain TF 
sites appeared to be a general trend in both cancer and aging processes, appearing at loci related to specific neuronal 
development and differentiation, including TFs such as NeuroG2, NeuroD1, Olig2 or Atoh1 (Dennis et al. 2019) and also 
involving Homeobox TFs such as DLX1/2.
To sum up, the analysis of the links between DNA methylation alterations and TF binding sites revealed that clear functional 
parallelisms between human and mouse exist in the aging scenario. This is in contrast to our earlier gene pathway 
enrichment analyses, which showed that most of the affected genetic pathways common in human and mouse involved 
cancer hypermethylation (of Polycomb-targets and developmental genes). This discrepancy could be explained by aging-
associated methylation changes being more functionally important when occurring at genomic sites not directly associated 
with gene locations (such as many TF binding sites). Moreover, as shown in earlier stages of this study (Fig. 2F and 3F), 
aging changes concentrate more at non-genic sites than cancer changes. Thus, the identification of functional targets 
implicated in DNA methylation alterations in aging may be more effective when focusing on transcription factor binding site 
alterations.
Interspecies integration of cancer and aging DNA methylation alterations
After establishing the parallel features of DNA methylation alterations in human and mouse, we integrated our CpG-specific 
data, to be able to directly compare methylation values between the two species at orthologous locations, by lifting the 
mouse coordinates to the human genome (see Methods). We recovered interspecies measurements for a sizeable set of 
59,100 CpG sites, 35% of which had been classified as dmCpGs at any comparison (see supplementary table 9 for the 
liftover statistics; the full list of orthologous sites is available as an extended dataset). These orthologous sites were over-
enriched in CpG island locations when compared to the original backgrounds (Fisher’s p-vals < 0.001, ORs = 7.1 and 6.1 
for human and mouse, respectively), and largely maintained their relationship to CpG islands in both species, suggesting 
that they covered similar functional regions in both genomes (Fig. 5A). Correlation analysis of the DNA methylation values 
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of the interspecies lifted CpGs revealed that, excluding cancer, the samples clustered within their species (Fig. 5B). 
Tumors, on the other hand, again showed widespread reconfiguration, clustering independently and, interestingly, mouse 
tumor CpGs were slightly more correlated to human tumors than to the rest of the mouse samples. Examining only non-
tumoral samples, methylation was found to be highly correlated between the two species (Fig. 5C, left panel; Pearson 
coef. 0.84, p-val < 0.001). Moreover, when we retained only CpG sites which were lowly variable within each species (SD 
< 0.1 methylation value) most of the species-discordant CpG sites disappeared (Fig. 5C, right panel; Pearson coef. 0.92, 
p-val < 0.001). Indeed, the subsets of high-variability sites for human and mouse (CpGs with SD >= 0.1 methylation value) 
showed much higher overlap than expected (Fig. 5D; Fisher’s p-val < 0.001, OR = 16.7), suggesting that locations of 
methylation variability are conserved between the two species. In order to strictly define species-discordant CpGs 
(sdCpGs), we performed a differential methylation analysis (FDR < 0.05, average change in methylation > 0.2) at the 
59,100 loci with interspecies measurements (the list of sites and sdCpGs is available as an extended dataset). We 
identified 1,845 sdCpGs (Fig. S11A), evenly split between those presenting higher and those lower methylation in mouse 
as compared to human (hyper- and hypo-sdCpGs, respectively, Fig. S11B). Interestingly, when annotating the sdCpGs 
either to human or mouse genomic contexts, we observed considerable differences in the distribution of the sites, 
especially according to their CpG island status (Fig. S11C-D). Following this observation, we directly assessed the 
transitions between the genomic contexts of the sdCpGs in the genome of each species (Fig. 5E), finding that, particularly 
in the case of hyper-sdCpGs, there was a considerable difference in the genomic association to CpG island status between 
the two species. In this case, CpGs which in human occupied CpG islands and in mouse occupied less-dense regions 
(shores, open sea) had higher methylation levels in mouse (i.e., were classified as hyper-sdCpGs). This is in line with our 
previous observations (Fig. 1F-H) of denser genomic loci being associated with lower methylation values in both species. 
This finding suggests that interspecies differences in DNA methylation levels may be partly explained by local changes in 
the functional genomic context of their respective genomes, such as CpG island membership (Hernando-Herraez, Garcia-
Perez, et al. 2015).
Next, we focused on the fraction of previously described species-specific cancer- or aging-associated dmCpGs for which 
we had interspecies measurements (see supplementary table 9 and extended datasets). This allowed us to directly 
compare cancer- and aging changes at specific loci between human and mouse. We found common and statistically 
significant intersections between the two species for all sets (Fig. 5F and supplementary table 10; SuperExactTest all p-
val < 0.001), with the biggest intersection being found for cancer dmCpGs, although the observed size and fold enrichment 
of the intersections was probably influenced by the differing sizes of the various sets. Differentiating by direction of change 
revealed that the biggest intersections were dominated by hypermethylation changes in both species (Fig. S12), especially 
when involving cancer sets. Aging, on the other hand, was limited to much smaller intersections with directionality not 
playing such an apparent role. Nonetheless, the observed intersections suggest that, added to the previously described 
similarities in genomic contexts (Fig. 4), when we focus on specific orthologous loci, common sites of DNA methylation 
alteration across the two diseases and the two species are readily detected.
After the characterization of specific similarities between human and mouse, we turned to examine the influence of 
sequence conservation in the explanation of the epigenetic patterns found. We integrated our data with UCSC 
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conservation scores for multiple alignments across vertebrate species (see Methods). First, regarding disease-associated 
alterations in general (dmCpGs), we observed that, for both species, cancer hypermethylation occurred at more conserved 
regions than did either cancer hypomethylation or aging changes (Fig. 5G). This finding can supports the notion that 
cancer hypermethylation may impact conserved axes of gene regulation across species, something which we had 
observed through the pathway enrichment analyses. However, these trends may also be partly explained by the genomic 
distribution of the alterations, because hypomethylation and aging alterations occur more often at intergenic and intronic 
regions (see Fig. 2F and 3F), which we found (using all the profiled CpGs) to be less conserved than other genetic regions 
such as exons or promoters, i.e., those more impacted by cancer hypermethylation in both species (Fig. S13A-B). Second, 
within our 59,100 interspecies loci, we found that sdCpGs were enriched at conserved regions (Fig. 5H) more frequently 
than the rest of the interspecies sites. This observation could at first sight appear to challenge the existing literature, which 
describes the positive correlation between sequence conservation and epigenetic conservation (Zhou et al. 2017), but, 
again, it may partly be explained by the sdCpGs being enriched at exon locations (see Fig. S11D), which are more 
conserved (see Fig. S13B). To address these issues, we applied stratified sampling to compare the CpG sets of interest 
against randomly-sampled background sets of CpGs which had matching distributions of gene locations. With this strategy, 
we found that most of the trends regarding the difference in conservation scores observed could indeed be partly explained 
by the genomic context of the CpGs involved, both for cancer- and aging dmCpGs (Fig. S14A) and for human- and mouse 
sdCpGs (Fig. S14B). These results suggest that both disease- and species-specific epigenetic traits are influenced by the 
genomic context surrounding the specific CpG sites involved.
Interspecies hotspots of cancer- and aging epigenetic deregulation
Finally, we used the interspecies CpGs to look for common hotspots of cancer- and aging epigenetic deregulation between 
human and mouse which could have downstream functional implications. We focused on the 22 CpGs which had been 
identified as dmCpGs in both species and both processes (described in Fig. 5F). Of these, 9 CpG sites presented 
concordant changes in both species (i.e., being deregulated in the same direction, in cancer and aging, for human and 
mouse) and were associated with a total of 6 genes (see supplementary table 12). In order to study the possible functional 
consequences of the DNA methylation alterations, we obtained TCGA expression data for the LGG-GBM glioma cohorts 
and analysed the expression of these candidate genes and their association with survival across glioma patients (see 
Methods). Notably, we found evidence of the strong deregulation of 5 out of the 6 genes in glioma samples as compared 
to controls (see below), indicating that our robust approach of looking at orthologous and concordant aging-cancer DNA 
methylation changes leads to the discovery of functionally relevant targets.
We first identified the AGAP3 gene as being a target of both cancer-associated and aging-associated deregulation in both 
human and mouse. AGAP3 is a component of the neural NMDA receptor complex and AGAP proteins regulate receptor 
trafficking in neurons (Oku and Huganir 2013). In cancer, this gene showed strong hypermethylation of internal CpG sites 
which, in both species, co-located with CpG islands upstream and downstream of many alternative transcripts (Fig. 6A, 
upper plots), while DNA methylation alterations in the same direction, albeit smaller, also appeared with aging in both 
species (Fig. 6A, lower plots). The specific location of the DNA methylation changes found hinted at a non-random and 
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perhaps functional role for the alterations. Thus we analysed AGAP3 expression in the TCGA LGG-GBM and found a 
strong decrease in expression in tumors (Fig. 6B, Wilcoxon rank-sum p-val < 0.001). Moreover, expression levels were 
strongly associated with overall survival in the cohort (Fig. 6C, log-rank test p-val < 0.001), with the more lethal GBM 
subtype having the lowest levels of expression and survival (Fig. S15A-B). Interestingly, as can be seen in Fig. 6A, the 
AGAP3 internal hypermethylation events co-located with the ending and start of several isoforms. We therefore explored 
the levels of the main AGAP3 isoforms (Fig. S15C) and their association with survival (Fig. S15D), discovering that a 
specific isoform (uc003wjf / ENST00000473312) was mostly explanatory of the effect (Fig. S15E, Cox Models log-rank 
test p-val < 0.001). Moreover, it corresponded to an isoform truncated close to the internal region targeted by the DNA 
methylation alterations (highlighted in Fig. 6A). Indeed, studies have described isoform variants of AGAP3 with biological 
functions (Oku and Huganir 2013) some of which may have roles in oncogenic processes through alterations in their mRNA 
expression (Shimizu et al. 2019). These observations exemplify an interspecies DNA methylation deregulation process 
which, as shown for human, could have a role in AGAP3 deregulation in glioma, possibly through an effect on isoform 
switching, with aging-associated methylation changes preluding the cancer-associated alterations.
In addition to AGAP3, 5 other genes were associated with concordant interspecies dmCpGs (Fig. 6D): GPRIN1, AJM1, 
LHX2, CCDC177 and TPGS1. Notably, 4 of the genes identified, much like with AGAP3, were clearly downregulated in 
tumoral samples as compared to healthy tissue (Fig. 6E, Wilcoxon rank-sum tests), with the GBM subtype often displaying 
the strongest downregulation. We also investigated their relationship with survival and found a strong association between 
gene expression and overall survival for GPRIN1, with a more modest effect for AJM1 and, interestingly, a trend for an 
association between CCDC177 expression and survival that was specific to the GBM subtype (Fig. S16). LHX2 is involved 
in neural development (Chou and Tole 2019), while GPRIN1 and TPGS1 play a role in neural cytoskeleton dynamics 
(Regnard et al. 2003; Nordman and Kabbani 2012) and AJM1 is related to apical junctions (Köppen et al. 2001). As such, 
the deregulated genes appear to be predominantly associated with cytoskeletal processes. LHX2 is known to be oncogenic 
in several types of cancer (Song et al. 2019) although we have found it to be downregulated in the case of glioma, as has 
been reported previously (Cheng et al. 2019). Nonetheless, the specific role of LHX2 and of the rest of the genes in glioma 
described here, or in cancer as a whole, remains largely unexplored.
CONCLUSIONS
In this work we have performed a systematic analysis of the DNA methylation dynamics associated with cancer and aging 
in brain tissue in human and mouse. We employed RRBS as a platform which allowed us to profile comparable genomic 
locations in both species. With this strategy, we first confirmed, in our study system, the parallelisms in baseline DNA 
methylation patterns between human and mouse. Subsequently, we explored the alterations associated with cancer and 
aging in both species. Our analyses revealed that there are considerable differences in the genomic and epigenomic 
features of DNA methylation alterations in cancer and aging, and that the particular characteristics of the alterations found 
for each process are globally conserved in human and in mouse (see Fig. S17 for a graphical outline of the main findings). 
We found specific parallelisms at the level of their genomic locations and the magnitude of the changes, the genetic 
pathways involved, the chromatin context of the alterations, the families of repetitive DNA elements affected and the 
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alteration of transcription factor regulation sites, among others. Interestingly, we observed that aging-associated changes 
in general seem to impact more specific functional gene pathways in mouse than in human. Nonetheless, we found that 
the classical hypermethylation of developmental gene pathways is more shared between cancer and aging in human than 
in mouse. Intriguingly, epigenetic alteration of satellite repeats appeared to be a feature of both aging and cancer in human, 
but not in mouse. Significantly, we found very clear interspecies similarities in the aging-associated alterations occurring 
at the transcription factor binding sites of specific families, suggesting that the functional impact of aging methylation 
changes could indirectly occur through transcription factor deregulation rather than through the direct targeting of specific 
genes. Finally, we derived a large set of orthologous CpG sites with interspecies measurements, which allowed us to 
observe that sites of epigenetic variability are conserved between the species, that interspecies differences between 
human and mouse can be partly explained by changes in the local genomic context associated with the CpG sites and 
that there are common interspecies loci which are altered during both aging and cancer.
The results presented in this manuscript cover several aspects of the epigenetic dynamics in human and mouse, but we 
should also draw attention to the limitations of our study. First, we recognize that the sample size used in our study design 
is limited (n = 3 per group), which is principally because of the substantial number of groups being analysed (4 phenotypes 
in 2 species). However, the interspecies corroboration of the results does indicate that the observed patterns are robust. 
Second, we have focused on a single tissue (brain). Although this allowed us to perform a comparative study in greater 
depth, and it is known that epigenetic alterations that arise in cancer or in aging are similar across tissues (Michalak et al. 
2019), it will be of value to explore the interspecies conservation of epigenetic signatures in other tissues (Maegawa et al. 
2017; Wang et al. 2017), and also other species such as pig or rhesus. Third, we used RRBS to profile analogous genomic 
locations in human and mouse, a technology which focuses on CpG-dense locations and is more limited when studying 
intergenic regions. That said, the use of RRBS allowed us to define a large subset of interspecies measurements (59,100 
CpG sites) with adequate coverage across all the samples.
From an evolutionary perspective, systematic multi-species comparisons are of great value in the understanding of the 
aetiology of disease. The uncovering of species-common pathways provides robust molecular explanations for the 
mechanisms at play, while interspecies differences may help explain the phenotypic divergences observed across the 
species. For instance, our observation of the human-specific epigenetic deregulation of zinc-finger genes in cancer may 
be related to the importance of this family in primates, which have experienced considerable lineage-specific expansion 
as compared to rodents (Huntley et al. 2006; Emerson and Thomas 2009). The emphasis on species-specific pathways, 
while relevant to evolutionary biology is, conversely, of less value in clinical biology, which seeks the translation of 
mechanisms to human. In this respect, systematic, genome-wide, multi-species integrative studies such as the one 
presented here have the potential to answer questions relating to both ends.
Taking a more clinical viewpoint, we can foresee that our results may spark interest in different areas. The mouse is one 
of the main preclinical models for human disease and, as such, it is essential to have markers for the prediction of treatment 
success in human (Day et al. 2015). In this vein, in this work we found that species-common epigenetic changes across 
diseases were readily associated with genes showing expression alterations in glioma in human. Thus, focusing on 
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conserved epigenetic alterations such as those described here may help narrow the search for functionally relevant targets 
that are altered in disease. In this sense, current advances in the development of targeted epigenetic editing tools (Liu et 
al. 2016), combined with the knowledge of epigenetic conservation in mouse and human, may serve as a powerful tool to 
explore the overall impact of both epigenetic and pathway alterations in multiple biological scenarios.
On the other hand, the set of epigenetically conserved DNA methylation sites could pave the way for the design and 
development of novel custom high-throughput platforms, either in the context of cost-effective microarray technology or 
through the use of more sophisticated targeted bisulfite sequencing approaches. This may be of particular interest within 
the framework of epigenetic profiling during drug screening in preclinical models as alterations of such conserved disease-
associated loci could help predict future treatment success in human. For example, glioma is a cancer type with a high 
prevalence of isocitrate dehydrogenase (IDH) mutations which lead to important epigenetic alterations (Han et al. 2020). 
The main chemotherapy treatment in glioma involves temozolomide (TMZ) (Hirst et al. 2013), and its effectiveness is also 
associated with various DNA methylation features beyond the well-known MGMT promoter methylation (Cheng et al. 2019). 
Thus, integrating epigenetic conservation knowledge could aid in the identification of drug-sensitive pathways in animal 
models, which in turn would improve the current standard-of-care treatments as well as also shed light on the mechanistic 
insights of novel compounds or those rescued from current drug repositioning approaches.
All in all, this work could constitute a baseline for other future studies focusing on the systematic evaluation of disease-
associated epigenetic patterns across multiple tissues and species from a multi-omic perspective in order to inform the 
search for inter- and intra-species patterns of epigenetic regulation.
MATERIALS AND METHODS
All statistical analyses were carried out using R statistical software (v3.6.2) unless stated otherwise. Software was 
managed through Bioconda (Grüning et al. 2018). Graphs were produced using R base functions and the ggplot2 R 
package (v3.2.1) (Wickham 2016). For the illustration and testing of multiple-set intersections, the UpSetR (v1.4.0) and 
SuperExactTest (v1.0.7) R packages were used (Wang et al. 2015; Conway et al. 2017). For the illustration of gene-level 
DNA methylation profiles, the ggbio R package (v1.34.0) was used (Yin et al. 2012).
Sample description and DNA extraction
Regarding the aging cohorts, we collected brain cortex tissue from 3 young (24, 33, 35 yr; female, male, male) and 3 old 
(65, 69, 70 yr; female, male, female) human subjects and 3 young (10 wk; all female) and 3 old (90 wk; all female) 
C57BL/6HsdOla/CBA mice. Humans and mice have different lifespans and in consequence their ages are not equally 
translatable across their different life stages. The young groups were selected to be at least sexually mature adults, a 
characteristic which is attained at 10 weeks for mice and 20 years for humans (Dutta and Sengupta 2016). Regarding the 
old groups and considering an average lifespan of 80 years and 24 months for humans and mice, respectively (Dutta and 
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Sengupta 2016), the 90-week-old mice would correspond to 69-year-old humans. Consequently, the age grouping for both 
species lies within a similar range.
For the cancer cohorts, we collected glioma and paired cortex tissue from 3 human subjects (71, 31, 44 yr; female, female, 
male), and glioma and paired cortex tissue from 3 mouse subjects (12-16 wk; all female) using an in-house murine model 
of glioma (see supplementary table 1 for additional information on the samples). The murine glioma model consists in 
the orthotopic allograft of GL261 glioma cells into the brain of C57BL/6 mice as previously described by us (Ferrer-Font et 
al. 2017). 
DNA was extracted by standard phenol-chloroform procedures. Concentration and quality of the DNA were assessed by 
Qubit fluorometry (Thermo Fisher Scientific) and Fragment Analyzer capillary electrophoresis (Agilent). Because the 
human cohorts were composed of both male and female individuals, sex chromosomes were not included in the 
subsequent analyses for any species (see below) in order to avoid sex bias.
Human samples and data from patients included in this study were provided by the following institutions: the Biobank HUB-
ICO-IDIBELL (PT17/0015/0024, integrated in the Spanish Biobank Network), the Biobank of Galicia Sur Health Research 
Institute (IISGS) and the Aragon Health Sciences Institute in the framework of the Biobank of Aragon. All human and 
mouse samples were processed following standard operation procedures with the appropriate approval of the 
corresponding Ethical and Scientific Review Boards: Bellvitge University Hospital Ethics Committee (code 07/19, 
11/04/2019) for the human aging samples; Biobank IISGS Ethics Committee (code 2019/238, 28/04/2019) and Aragón 
Clinical Research Ethics Committee (code 14/2019, 24/07/2019) for the human cancer samples; Health Institute Carlos III 
Ethics Committee (code CBA PA 13_2013, 26/02/2013) for the mouse aging samples; Autonomous University of 
Barcelona Ethics Commission (code CEEAH-3665, 05/02/2018) for the mouse cancer samples.
Reduced representation bisulfite sequencing
For each sample, 100 ng of genomic DNA were used for library preparation with the Premium Reduced Representation 
Bisulfite Sequencing Kit (Diagenode). Subsequently, samples were pooled in groups of 6 or 8. PCR clean-up after the final 
library amplification was performed using Agencourt AMPure XP (Beckman Coulter). The quality of the pools was assessed 
by Qubit fluorometry (Thermo Fisher Scientific) and Fragment Analyzer capillary electrophoresis (Agilent). Finally, the 
library pools were sequenced. Human samples were sequenced on a NovaSeq6000 (Illumina) using 50 bp paired-end 
read sequencing (PE50). Mouse samples were sequenced on a HiSeq3000 (Illumina) using 50 bp single-read sequencing 
(SR50).
Reduced representation bisulfite sequencing data preprocessing
FASTA quality was assessed with FastQC (v0.11.8; https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Reads 
were quality- and adapter-trimmed with Trim galore (v0.6.4; 
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https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) with default parameters under --rrbs mode and --2colour 
20 in the case of the human data to account for NovaSeq bias towards identifying high-quality G bases from non-signal 
basecalls. Next, the reads were aligned to pre-indexed and bisulfite converted GRCh38/hg38 and GRCm38/mm10 
genomes (primary assemblies) with Bismark (v0.22.2) using default parameters (Bowtie 2 alignment; see supplementary 
table 1 for additional information on the alignment statistics) (Krueger and Andrews 2011). Finally, methylation counts for 
cytosines belonging to CpG sites were obtained with Bismark’s methylation extractor under default parameters, including 
--no_overlap for paired-end data to avoid scoring overlapping methylation calls twice. For each position, methylation values 
were computed as the percentage of methylated cytosines with respect to total cytosines on a scale of 0 to 1.
Differential methylation analyses
Differential methylation analyses were performed on CpG sites, not on individual cytosines, using the following process: 
1) the counts for cytosines from both strands belonging to the same CpG site were pooled so as to have one methylation 
measurement per CpG site; 2) CpG sites mapping to sex chromosomes and alternative haplotypes were filtered out; 3) 
CpG sites were filtered for low coverage (< 10 counts) or very high coverage (> 99th percentile); 4) CpG sites common to 
all human or mouse samples were retained for the analyses. Next, the differential methylation analyses were carried out 
with the methylKit R package (v1.14.2) (Akalin et al. 2012) using the calculateDiffMeth function with default parameters 
and multiple testing adjustment by FDR < 0.05. The calculateDiffMeth function uses logistic regression models to define 
differentially methylated CpGs between groups. Because of the low number of samples (n = 3 per group), a strict threshold 
of > 0.2 change in methylation value was used to define significant changes. No other covariates were included in the 
models because of the limited information available for other variables. Nonetheless, the inclusion of sex or age variables 
in the human cancer and aging comparisons led to similar results, with 97-99% of the dmCpGs being the same (data not 
shown).
Annotation of sites to genomic locations
The profiled CpG sites were annotated to hg38 or mm10 CpG islands and gene locations using the annotatr R package 
(v1.12.1) (Cavalcante and Sartor 2017). Overlapping genetic annotations were collapsed with the following priority: 
Promoter > 5UTR > 3UTR > Exon > Intron > 1to5 > Intergenic. Finally, CpG sites were mapped to genes and their 
transcripts through the TxDb.Hsapiens.UCSC.hg38.knownGene and TxDb.Mmusculus.UCSC.mm10.knownGene R 
packages (v3.1.0). Annotation for the Illumina Infinium Human Methylation 450K Beadchip was accessed through the 
IlluminaHumanMethylation450kanno.ilmn12.hg19 R package (v0.6.0). 
To determine the density in surrounding CpGs associated with each site, each locus was expanded to a 2000 bp window 
and the number of CpGs present in the surrounding genomic sequence were counted and divided by the number of those 
possible.
Gene set enrichment analyses
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Gene set enrichment analyses were performed with the goseq R package (v1.38.0) [2010 P Genome Biol - Young MD]. 
CpGs were mapped to genes, and enrichment in biological functions was carried out with genes that were exclusively 
hyper- or hypomethylated, using appropriate filtered backgrounds of assayed genes. The bias arising from there being 
different number of probes per gene was taken into account in the analyses. The GO, KEGG, Reactome and CGP gene 
set databases from the Molecular Signature Database (MSigDB v7.0) (Liberzon et al. 2015) were used for the enrichment 
analyses and were accessed through the msigdbr R package (v7.0.1). In order to retain the most important enrichments, 
only gene sets with FDR < 0.05, OR > 2 and containing between 10 and 1,000 genes were represented as statistically 
significant.
Region enrichment analyses
Genomic enrichment analyses were performed with the LOLA R package (v1.16.0) (Sheffield and Bock 2016) using custom 
databases. Sets of CpGs were tested for over-enrichment in specific genomic tracks using one-sided Fisher’s exact tests 
(FDR < 0.05) with appropriate filtered backgrounds of the CpGs being used for each case. The genomic regions analysed 
included histone marks, chromatin states and repetitive DNA elements. The histone and chromatin state LOLA databases 
built for the enrichments are available as extended datasets.
Histone ChIP-seq BED tracks for H3K4me1, H3K4me3, H3K36me3, H3K27ac, H3K27me3, and H3K9me3 in 15 healthy 
human tissues were obtained from LOLA extended universe (databio.org/regiondb) using NIH Roadmap Epigenomics 
region data corresponding to the hg38 version of the human genome (Roadmap Epigenomics Consortium et al. 2015). 
Histone BED tracks for the aforementioned marks in 9 post-natal mouse tissues mapped to the mm10 version of the mouse 
genome were obtained from ENCODE (Gorkin et al. 2020).
Chromatin states were built using chromHMM (see below). Consolidated data from the aforementioned 6 histone tracks 
(BED tag.align files) and corresponding ChIP-seq input from 15 human tissues was obtained from NIH Roadmap 
Epigenomics (https://egg2.wustl.edu/roadmap/data/byFileType/alignments/consolidated). Data corresponding to the 
aforementioned 6 histone ChIP-seq tracks (BAM files) and the corresponding ChIP-seq input from 9 mouse tissues were 
obtained from ENCODE (https://www.encodeproject.org/).
Repetitive regions identified by RepeatMasker in the hg38 or mm10 genomes (Smit 1996) were obtained with the UCSC 
Table Browser (Karolchik 2004) and grouped by family or class. Elements with an uncertain classification, labelled with 
the “?” symbol, were filtered out.
Chromatin state model learning
ChromHMM (v1.18) (Ernst and Kellis 2012) was used to generate an 18-state model to predict chromatin states from 15 
human and 9 mouse tissues. ChIP-seq datasets corresponding to 6 histone marks (H3K4me1, H3K4me3, H3K36me3, 
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H3K27ac, H3K27me3, and H3K9me3), along with their respective input controls, were obtained from NIH Roadmap 
Epigenomics and ENCODE for human and mouse samples respectively (see supplementary table 11 for the description 
of the files). Human BED files were converted from hg19 to hg38 coordinates via UCSC’s liftOver tool (v377) (Hinrichs 
2006). Resulting files were binarized using the binarizeBed function with default parameters using the hg38 chromosome 
sizes. A model considering 18 states was learned using the LearnModel function with default parameters, as previously 
described elsewhere (Roadmap Epigenomics Consortium et al. 2015). In the case of mouse datasets (mm10), BAM files 
corresponding to replicated samples from different mouse tissues were merged using SAMtools (v1.7) (Li et al. 2009), as 
previous studies have suggested that chromatin state inferences either from single time series or from replicated data are 
invariably consistent and highly reproducible. Read duplicates were removed using the MarkDuplicates function from 
Picard tools (broadinstitute.github.io/picard/). The resulting BAM files were sorted using SAMtools and binarized using the 
binarizeBam function from chromHMM. A model considering 18 states was learned using the LearnModel function using 
the same conditions as the human chromHMM pipeline. For both human and mouse analyses, the resulting chromatin 
states were reordered and renamed to facilitate later interpretation purposes. In addition, enrichment analyses of the 
different chromatin states in external genomic datasets (CpG Islands, RefSeq Exons, RefSeq genes, RefSeq transcription 
start sites, RefSeq transcript end sites and regions within 2000 base pairs of a RefSeq TSS) obtained from the UCSC 
genome browser (hg38 and mm10 genomes) were performed using the OverlapEnrichment function from chromHMM.
Motif enrichment analyses
Transcription factor motif enrichment analyses were performed with Hypergeometric Optimization of Motif EnRichment 
(HOMER) software (v4.11.1) (Heinz et al. 2010) for cancer- and aging dmCpGs in human and mouse, using the hg38 or 
mm10 genomes as reference. HOMER was run under default settings and with the -keepOverlappingBg parameter, using 
as background the filtered universe of CpG sites analysed by the RRBS for human and mouse, respectively. Significant 
enrichments for known transcription factors were first filtered by FDR < 0.05, and subsequently only the top 50 results 
ordered by enrichment with respect to the background were retained for each comparison (see supplementary table 8 
for full results).
Liftover of orthologous CpGs
Liftover of mm10 to hg38 coordinates was performed with UCSC’s liftOver tool (v377) (Hinrichs 2006) by using chain files 
from http://hgdownload.soe.ucsc.edu/goldenPath/. Lifted CpG sites which did not reciprocally lift back from hg38 to the 
original mm10 coordinates were discarded (~ 2%).
Conservation analyses
Base-resolution PhastCons tracks for 100-way (hg38) and 60-way (mm10) alignments (Siepel et al. 2005) were accessed 
via the GenomicScores R package (v1.1.10) (Puigdevall and Castelo 2018).
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Gene expression analyses
Gene and isoform-level gene expression data in the form of RSEM counts and curated survival data were accessed via 
the Broad Institute Genomic Data Analysis Center (http://gdac.broadinstitute.org/runs/stddata__2016_01_28/data/) and 
the UCSC Xena (https://xenabrowser.net/datapages/) for the glioma GBMLGG (glioblastoma - lower grade glioma) cohort 
from the TCGA (The Cancer Genome Atlas) consortium (Brennan et al. 2013; Ceccarelli et al. 2016) (the list of patients 
and genes analysed is available as an extended dataset). Prior to analysis, data were normalized by the VST (variance 
stabilizing transformation) procedure using the DESeq2 R package (v1.26.0) (Anders and Huber 2010). This 
transformation stabilizes the variance-mean relationship in the data and corrects for differences in library size between the 
samples. For the isoform analysis, the 4 most expressed AGAP3 isoforms were selected. Cox models were analysed with 
the survival R package (v3.1.11) (Therneau and Grambsch 2000).
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FIGURE LEGENDS
Fig. 1. Baseline epigenomic patterns in human and mouse. (A) Schematic of the study design. (B) Heatmaps showing the 
pairwise Pearson correlations between DNA methylation levels of the profiled CpG sites across samples. (C) Violin plots 
of global levels of DNA methylation for the pooled samples (red dots indicate average values; h = human, m = mouse; 
tumor samples are excluded). (D and E) Barplots indicating the distribution of the profiled CpG sites in human and mouse 
across CpG island and gene-region locations. (F and G) Violin plots showing the DNA methylation levels for the pooled 
samples with the CpG sites grouped by CpG island locations and gene-region locations (red dots indicate average values). 
(H) Density plots indicating the relationship between DNA methylation values and surrounding density (2kb bins) in CpG 
sites for the profiled CpGs. (I and J) Heatmaps and bubble plots showing the significant over-enrichments in log2(odds 
ratio) of CpG sites classified as high-, medium- and low-methylation in ChIP-seq peak locations of different histone marks 
across a panel of tissues or in the locations of repetitive DNA classes across the human and mouse genomes.
Fig. 2. Cancer and aging DNA methylation alterations in human. (A) Violin plots of global levels of DNA methylation of all 
CpGs across the profiled samples (N = non-tumor, T = tumor, Y = young, O = old). (B) PCA plots showing the distribution 
of the samples across the first two principal components, with the percentage of variance each explains. (C) Heatmaps 
showing the methylation values of the top 1,000 dmCpGs found in the aging and cancer comparisons. (D) Barplots 
indicating the relative numbers of hyper- and hypo-dmCpGs (differentially methylated CpGs) in aging and cancer. (E and 
F) Barplots indicating the distribution of the dmCpGs across CpG island and gene-region locations, including the 
distribution of the universe of CpGs profiled by the RRBS (“all”). (G) Lollipop plots comparing the number of dmCpGs 
mapped to genes (left vertical axis, black dots) with the number of different genes that the dmCpGs mapped to (right 
vertical axis, orange dots). (H) UpSet plot describing the dmCpG sets and their intersections, indicating the size of the sets 
and the fold-enrichment (FE) of the intersections based on their expected overlaps.
Fig. 3. Cancer and aging DNA methylation alterations in mouse. (A) Violin plots of global levels of DNA methylation of all 
CpGs across the profiled samples (N = non-tumor, T = tumor, Y = young, O = old). (B) PCA plots showing the distribution 
of the samples across the first two principal components, with the percentage of variance each explains. (C) Heatmaps 
showing the methylation values of the top 1,000 dmCpGs found in the aging and cancer comparisons. (D) Barplots 
indicating the relative numbers of hyper- and hypo-dmCpGs (differentially methylated CpGs) in aging and cancer. (E and 
F) Barplots indicating the distribution of the dmCpGs across CpG island and gene-region locations, including the 
distribution of the universe of CpGs profiled by the RRBS (“all”). (G) Lollipop plots comparing the number of dmCpGs 
mapped to genes (left axis, black dots) with the number of different genes that the dmCpGs mapped to (right axis, orange 
dots). (H) UpSet plot describing the dmCpG sets and their intersections, indicating the size of the sets and the fold-
enrichment (FE) of the intersections based on their expected overlaps.
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Fig. 4. Chromatin landscape of aging and cancer DNA methylation alterations in human and mouse. (A and B) Heatmaps 
showing the significant over-enrichments in log2(odds ratio) of hyper- and hypo-dmCpGs in the cancer and aging 
comparisons, for human and mouse in ChIP-seq peak locations of different histone marks across a panel of tissues or in 
chromatin states built across the same panel of tissues. (C) Bubble plots showing the significant over-enrichments in 
log2(odds ratio) of hyper- and hypo-dmCpGs in the cancer and aging comparisons in the locations of repetitive DNA 
classes across the genome for human and mouse. (D) Barplots indicating the relative numbers of transcription factors, 
classified by their domains, whose motifs were found to be significantly enriched (HOMER analysis, FDR < 0.05) at the 
genomic locations of the different dmCpG sets, compared to the numbers of all of the transcription factors tested (“all”). 
Only the top 50 most enriched, significant factors for each set were selected.
Fig. 5. Interspecies DNA methylation alterations in human and mouse. (A) Sankey diagram describing the distribution of 
changes in the CpG island status of the 59,100 interspecies orthologous CpGs when considering either the human or the 
mouse genomic annotation. On either side, the original backgrounds of all the profiled CpG sites are shown. (B) Heatmap 
showing the pairwise Pearson correlations of the DNA methylation levels of the interspecies CpGs across all samples. (C) 
Scatter plots showing the correlation between DNA methylation levels at all the profiled interspecies sites (left plot) or 
excluding intra-species highly variable CpG sites with SD >= 0.1 methylation value (right plot) (tumors excluded). (D) Venn 
diagram showing the intersection of interspecies lifted CpG sites classified as highly variable within each species (SD >= 
0.1 methylation value) for both mouse and human. (E) Sankey diagrams showing the distribution of hyper- and hypo-
sdCpGs (species-discordant CpGs) across CpG island locations, taking into account the differences in the genomic context 
of the human and mouse genome. (F) UpSet plot describing the sets of cancer and aging dmCpGs with interspecies 
measurements, showing their sizes and intersections between human and mouse. (G) Violin plots showing the distribution 
of phastCons conservation scores for the detected aging- and cancer dmCpGs in human and mouse, compared to the 
profiled RRBS background (red dots indicate average values). (H) Violin plots showing the distribution of phastCons scores 
for the detected interspecies sdCpGs, compared to the 59,100 lifted background, either in human or mouse-centered 
conservation score (red dots indicate average values).
Fig. 6. AGAP3 is an interspecies cancer- and aging-associated target of DNA methylation alterations. (A) Plots describing 
the average methylation values of tumoral, non-tumoral, young and old samples in human and mouse across the profiled 
CpG sites mapping to AGAP3. Sites marked in yellow represent significant dmCpGs in the aging and cancer comparisons. 
Below, the transcripts and CpG islands associated with the genomic region described are shown. (B) Boxplots showing 
the expression values of the AGAP3 gene in control and tumor samples from the TCGA glioma cohort (GBM-LGG). 
Expression is measured in VST (variance stabilizing transformation) normalized units. High and low-expression samples 
(above and below the median) are in yellow and green. (C) Survival curves showing the association of high and low AGAP3 
expression groups with overall survival across glioma patients. (D) Boxplots describing the methylation values of the 
interspecies dmCpGs that presented concordant changes in cancer and aging across human and mouse and which were 
associated with specific genes. (E) Boxplots showing the expression values (VST normalized units) of the genes 
associated with the interspecies concordant dmCpGs in control and tumoral samples from the TCGA glioma cohort (GBM-
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LGG). Glioblastoma (GBM) and lower grade glioma (LGG) samples are shown separately. High- and low-expression 
samples (above and below the median) are colour-coded. Wilcoxon rank-sum tests: * = p-val < 0.05, ** = p-val < 0.001, 
*** = p-val < 0.0001, “ns” = p-val > 0.05.  
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